Date:6/10/2009

hildren, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; Percocet(R) and Percodan(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R) Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by Novartis AG; SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R) for the palliative treatment of advanced prostate cancer, and SUPPRELIN(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, endocrinology and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the acquisition of Indevus, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance"
'/>"/>

SOURCE Endo Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. FDA Orders Label Warning for Testosterone Gels
2. Testosterone Injections Offer Hope for Male Contraceptive
3. Injectable testosterone may provide effective male contraception
4. Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
5. Male Hormone Replacement Company Renewman.com Critical of MLB for Testosterone Abuse Publicity
6. Womens Testosterone Patch May Not Work
7. Prostate cancer drug reduces testosterone levels in as little as 3 days
8. Study shows testosterone improves sexual well-being in post-menopausal women
9. Testosterone Patch Restores Libido in Postmenopausal Women
10. Testosterone key to disease transmission
11. AUDIO from Medialink and Solvay: Men Suffering From Symptoms of Low Testosterone Should Talk to Their Doctor